Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | APAF1 | O14727 | 1/20 | 0.43 |
| ▸ | TDP2 | O95551 | 1/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | GALK1 | P51570 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.43 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.43 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15731795 | 0.87 | PIK3R1 (0.39) | LMNAMAPTSMN1; SMN2RAD51MEN1 | |
| SCHEMBL17576245 | 0.85 | AKR1C3 (0.44) | MAPTSMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL20050092 | 0.85 | ALDH1A1 (0.42) | LMNAMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL1919863 | 0.85 | AKR1C3 (0.44) | MAPTSMN1; SMN2RAD51MEN1KMT2A | |
| SCHEMBL6330031 | 0.85 | KMT2A (0.49) | LMNAMAPTSMN1; SMN2RAD51MEN1 | |
| SCHEMBL29483984 | 0.85 | RAD51 (0.51) | MAPTSMN1; SMN2RAD51MEN1KMT2A | |
| SCHEMBL8014932 | 0.85 | MAPT (0.40) | LMNAMAPTSMN1; SMN2RAD51MEN1 | |
| SCHEMBL20694863 | 0.84 | GSK3B (0.39) | RAD51 | |
| SCHEMBL18028120 | 0.84 | ALDH1A1 (0.42) | MAPTSMN1; SMN2RAD51MEN1KMT2A | |
| SCHEMBL18058760 | 0.84 | PTGS2 (0.41) | MAPTSMN1; SMN2MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119241539-A | Pyrazolo piperidine (ketone) -containing derivative, and preparation method and application thereof | 沈阳药科大学 | 2025-01-03 | — | — | CN | disclosed |
| WO-2017187245-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF APIXABAN | OPTIMUS DRUGS (P) LIMITED (IN) | 2017-11-02 | — | — | WO | disclosed |
| EP-2310389-B1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | AMGEN INC (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20110118285-A1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | AMGEN INC. | 2011-05-19 | — | — | US | disclosed |
| EP-2310389-A1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | Amgen Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| WO-2009143477-A1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | AMGEN INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| EP-1467984-A4 | SYNTHESIS OF 4,5-DIHYDRO-PYRAZOLO (3,4-C) PYRID-2-ONES | BRISTOL MYERS SQUIBB CO (US) | 2005-12-07 | — | — | EP | disclosed |
| CN-1639147-A | Synthesis of 4, 5-dihydro-pyrazolo [3, 4-c ] pyridin-2-ones | BRISTOL MYERS SQUIBB CO (US) | 2005-07-13 | — | — | CN | disclosed |
| EP-1467984-A2 | SYNTHESIS OF 4,5-DIHYDRO-PYRAZOLO (3,4-C) PYRID-2-ONES | Bristol-Myers Squibb Company (US) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003049681-A2 | SYNTHESIS OF 4,5-DIHYDRO-PYRAZOLO [3,4-C] PYRID-2-ONES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118285-A1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | HGF, HGFAC, MET | LMNA 4022/4885MAPT 2627/4885SMN1; SMN2 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.